These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 36251386)
1. Case Report: Blepharospasms After the Use of Long-Acting Paliperidone Injections. Contrucci RR; Heikens M; Beex-Oosterhuis MM J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):608-609. PubMed ID: 36251386 [No Abstract] [Full Text] [Related]
2. Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report. Langley-DeGroot M; Joshi Y; Lehman D; Rao S J Clin Psychopharmacol; 2016 Jun; 36(3):277-9. PubMed ID: 27043124 [No Abstract] [Full Text] [Related]
3. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic. Lai JK; Margolese HC Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989 [No Abstract] [Full Text] [Related]
4. Hypothermia Associated With Paliperidone Depot Injection in Schizophrenia Patient: A Case Report. Hirapara K; Munir A; Aggarwal R J Clin Psychopharmacol; 2020; 40(1):86-87. PubMed ID: 31834087 [No Abstract] [Full Text] [Related]
6. Serum Concentration of Paliperidone Palmitate Administered Every 3 Weeks. Cohen JY; Dumoulin-Charette A; Meraabi N; Poirier R Psychopharmacol Bull; 2019 Jun; 49(2):57-62. PubMed ID: 31308584 [TBL] [Abstract][Full Text] [Related]
7. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266 [TBL] [Abstract][Full Text] [Related]
8. Postinjection Syndrome After Paliperidone? Žmitek A; Jovan Z J Clin Psychopharmacol; 2023 Sep-Oct 01; 43(5):471-472. PubMed ID: 37683244 [No Abstract] [Full Text] [Related]
9. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570 [TBL] [Abstract][Full Text] [Related]
11. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia. Jarema M; Bieńkowski P; Heitzman J; Parnowski T; Rybakowski J Psychiatr Pol; 2017 Feb; 51(1):7-21. PubMed ID: 28455891 [TBL] [Abstract][Full Text] [Related]
12. Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration. Suzuki H; Hibino H; Inoue Y; Takaya A Asian J Psychiatr; 2018 Jun; 35():28. PubMed ID: 29751217 [No Abstract] [Full Text] [Related]
14. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. Alphs L; Bossie C; Mao L; Lee E; Starr HL Early Interv Psychiatry; 2018 Feb; 12(1):55-65. PubMed ID: 26403322 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950 [TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement. Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907 [TBL] [Abstract][Full Text] [Related]
18. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188 [TBL] [Abstract][Full Text] [Related]
19. Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration. Procyshyn RM; Banasch JL; Barr AM; Honer WG J Psychiatry Neurosci; 2016 Apr; 41(3):E56-7. PubMed ID: 27116902 [No Abstract] [Full Text] [Related]
20. Peripheral edema: An easily overlooked side effect of long-acting injectable paliperidone. Ho YC; Hu LY; Liou YJ Aust N Z J Psychiatry; 2021 Oct; 55(10):1023. PubMed ID: 33636990 [No Abstract] [Full Text] [Related] [Next] [New Search]